Sotera Health Valuation
Is SHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SHC?
Other financial metrics that can be useful for relative valuation.
|What is SHC's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SHC's PE Ratio compare to its peers?
|SHC PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
STVN Stevanato Group
MEDP Medpace Holdings
SYNH Syneos Health
ABCL AbCellera Biologics
SHC Sotera Health
Price-To-Earnings vs Peers: SHC is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (23.5x).
Price to Earnings Ratio vs Industry
How does SHC's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: SHC is good value based on its Price-To-Earnings Ratio (17x) compared to the US Life Sciences industry average (26.4x)
Price to Earnings Ratio vs Fair Ratio
What is SHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||16.9x|
|Fair PE Ratio||30x|
Price-To-Earnings vs Fair Ratio: SHC is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (30x).
Share Price vs Fair Value
What is the Fair Price of SHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SHC ($7.41) is trading below our estimate of fair value ($29.99)
Significantly Below Fair Value: SHC is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.